Free Trial
OTCMKTS:MEDXF

Medexus Pharmaceuticals (MEDXF) Stock Price, News & Analysis

Medexus Pharmaceuticals logo
$2.27 -0.03 (-1.27%)
As of 07/3/2025 12:44 PM Eastern

About Medexus Pharmaceuticals Stock (OTCMKTS:MEDXF)

Key Stats

Today's Range
$2.27
$2.34
50-Day Range
$1.85
$2.48
52-Week Range
$1.27
$3.88
Volume
6,756 shs
Average Volume
23,935 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Strong Buy

Company Overview

Receive MEDXF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medexus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MEDXF Stock News Headlines

Trump’s New Order Could Boost Social Security Benefits by 400%
If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President Trump's Executive Order #14196 could not only save Social Security from collapse... ...but potentially increase benefits by up to 400%, according to legendary investor Louis Navellier.
See More Headlines

MEDXF Stock Analysis - Frequently Asked Questions

Medexus Pharmaceuticals' stock was trading at $2.4150 at the beginning of the year. Since then, MEDXF shares have decreased by 6.0% and is now trading at $2.2710.

Shares of MEDXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
OTCMKTS:MEDXF
CIK
N/A
Fax
N/A
Employees
98
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (OTCMKTS:MEDXF) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners